We are live on ! Find out more
ACHN

Achillion Pharmaceuticals
ACHN

Delisted

ACHN was delisted on the 27th of January, 2020.

Back to rankings

93 hedge funds and large institutions have $263M invested in Achillion Pharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 28 increasing their positions, 37 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

568% more call options, than puts

Call options by funds: $42.6M | Put options by funds: $6.38M

7% more capital invested

Capital invested by funds: $245M → $263M (+$17.6M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

9% less funds holding

Funds holding: 102 → 93 (-9)

24% less repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 37

31% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 26

Holders
93
Holders Change
-9
Holders Change %
-8.82%
% of All Funds
2.7%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
18
Increased
28
Reduced
37
Closed
26
Calls
$42.6M
Puts
$6.38M
Net Calls
+$36.2M
Net Calls Change
-$12.6M

Top Buyers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
+$25.9M
2
State Street
State Street
Massachusetts
+$5.71M
3
BC
Broadfin Capital
New York
+$2.9M
4
VAM
Visium Asset Management
New York
+$2.68M
5
DAM
Doheny Asset Management
California
+$2.64M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$16.7M
2
JHIU
Janus Henderson Investors US
Colorado
-$7.28M
3
UBS AM
UBS AM
Illinois
-$5.98M
4
Wells Fargo
Wells Fargo
California
-$4.45M
5
WSA
Wall Street Associates
California
-$3.48M
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$77.6M +$25.9M +8,908,946 +62%
QF
2
QVT Financial
New York
$35.9M -$2.6M -896,000 -8%
State Street
3
State Street
Massachusetts
$20.5M +$5.71M +1,968,372 +47%
Vanguard Group
4
Vanguard Group
Pennsylvania
$15.6M +$1.05M +363,388 +8%
Capital World Investors
5
Capital World Investors
California
$13.7M – – –
BFA
6
BlackRock Fund Advisors
California
$11.5M -$207K -71,323 -2%
BIT
7
BlackRock Institutional Trust
California
$9.92M +$828K +285,301 +11%
State of Wisconsin Investment Board
8
State of Wisconsin Investment Board
Wisconsin
$8.66M +$1.77M +609,640 +30%
Goldman Sachs
9
Goldman Sachs
New York
$7.96M +$362K +124,721 +5%
BB
10
BB Biotech
Switzerland
$5.91M – – –
Northern Trust
11
Northern Trust
Illinois
$4.55M -$15K -5,158 -0.4%
BC
12
Broadfin Capital
New York
$3.32M +$2.9M +1,000,000 New
DAM
13
Doheny Asset Management
California
$3.25M +$2.64M +910,375 +1,346%
VAM
14
Visium Asset Management
New York
$3.06M +$2.68M +922,579 New
Morgan Stanley
15
Morgan Stanley
New York
$2.56M +$1.76M +605,323 +369%
AQR Capital Management
16
AQR Capital Management
Connecticut
$2.17M +$1.87M +645,055 +6,358%
BA
17
BlackRock Advisors
Delaware
$2.11M -$189K -65,143 -9%
Group One Trading
18
Group One Trading
Illinois
$2.11M +$1.84M +634,972 New
Wellington Management Group
19
Wellington Management Group
Massachusetts
$2.03M -$480K -165,500 -21%
First Eagle Investment Management
20
First Eagle Investment Management
New York
$1.99M +$1.74M +600,000 New
RA
21
Royce & Associates
New York
$1.96M +$1.71M +590,000 New
Bank of New York Mellon
22
Bank of New York Mellon
New York
$1.53M -$39.1K -13,475 -3%
BBA
23
Baker Bros. Advisors
New York
$1.51M – – –
SM
24
Sabby Management
Florida
$1.5M -$91.4K -31,499 -6%
D.E. Shaw & Co
25
D.E. Shaw & Co
New York
$1.38M +$542K +186,775 +81%
1
2 3 4 5

ACHN Hedge Fund Activity: Q4 2013 in Review

93 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Achillion Pharmaceuticals (ACHN) for Q4 2013, worth a combined $263M — up 7.2% from $245M a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of ACHN and 18 opened new positions — a net loss of 8 holders — while 37 trimmed existing stakes and 28 added.

The largest buyer was RA Capital Management, adding an estimated $25.9M. The largest seller was Fidelity Investments, cutting an estimated $16.7M.

  • 93 institutional investors held Achillion Pharmaceuticals (ACHN) as of Q4 2013, down from 102 in Q3 2013.
  • Funds reported $263M of Achillion Pharmaceuticals stock for Q4 2013, up 7.2% quarter-over-quarter.
  • 18 funds opened new Achillion Pharmaceuticals positions in Q4 2013 and 26 closed out, a net change of -8 holders.
  • The largest Achillion Pharmaceuticals buyer in Q4 2013 was RA Capital Management, an estimated $25.9M added.
  • The largest Achillion Pharmaceuticals seller in Q4 2013 was Fidelity Investments, an estimated $16.7M sold.

Based on aggregated 13F filings for Q4 2013.